Is It Too Late to Buy Vaxart Stock?
On June 11, Vaxart (NASDAQ: VXRT) stock skyrocketed 22% after Piper Sandler analyst Yasmeen Rahimi initiated coverage of the company with a price target of $18. In setting the price target, the analyst cited the validation of the company's novel adenoviral platform, Ad5, in 200 clinical studies. Vaxart is using the technology to develop a novel, pill-based oral coronavirus vaccine candidate.